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The cellular and molecular bases of neurological diseases have been studied for decades; however, the underlying mechanisms
are not yet fully elucidated. Compared with other disorders, diseases of the nervous system have been very difficult to study
mainly due to the inaccessibility of the human brain and live neurons in vivo or in vitro and difficulties in examination of human
postmortem brain tissue. Despite the availability of various genetically engineered animal models, these systems are still not
adequate enough due to species variation and differences in genetic background. Human induced pluripotent stem cells (hiPSCs)
reprogrammed from patient somatic cells possess the potential to differentiate into any cell type, including neural progenitor cells
and postmitotic neurons; thus, they open a new area to in vitro modeling of neurological diseases and their potential treatment.
Currently, many protocols for generation of various neuronal subtypes are being developed; however, most of them still require
further optimization. Here, we highlight accomplishments made in the generation of dopaminergic and cholinergic neurons, the
two subtypesmost affected in Alzheimer’s and Parkinson’s diseases and indirectly affected inHuntington’s disease. Furthermore, we
discuss the potential role of hiPSC-derived neurons in themodeling and treatment of neurological diseases related to dopaminergic
and cholinergic system dysfunction.
1. Introduction
The majority of underlying mechanisms related to human
neurological dysfunction are not fully examined. Most of the
current knowledge about neurodevelopmental and neurode-
generative disorders focuses on studies of postmortem nerve
tissues, spinal cords, and brains or cancer tissue (e.g., neu-
roblastoma). Due to the limited access to neuronal samples
from postmortem organs and the restricted possibilities for
directly examining live human neurons, the current under-
standing of the cellular and molecular mechanism of these
diseases is restricted. Additionally, studies with tissues from
autopsies that often represent the end stage of the disease
do not always reveal information on the course of disease.
A significant contribution for elucidating the pathogenesis of
various neurological abnormalities has been represented by
transgenic animalmodels that canmimic human diseases [1].
Transgenic/knockout technologies provide a useful tool for
investigation of diseasemechanism. However, animalmodels
do not fully recapitulate complex human disease phenotypes
and very often are limited only for monogenic disorders.
Recent discoveries in pluripotent stem cell technology
provide a new opportunity to overcome these limitations.
Production of human pluripotent stem cells (hPSCs) from
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different somatic lineages can be seen as a novel tool that
allows the development of treatments for humanneurological
disorders through disease modeling, drug screening, and
regenerative medicine.
Human embryonic stem cells (hESCs) first established
by Thomson et al. [2] and hiPSCs developed by Yamanaka’s
group [3], as the main types of hPSCs, both show unlimited
self-renewal properties and the ability to differentiate into
cells of all three germ layers [4].
Currently, many neurological diseases show dramatically
increasing trends and, with the aging populations of devel-
oped countries, potential treatments are needed urgently.
Nowadays, Alzheimer’s and Parkinson’s diseases are the most
common progressive neurodegenerative disorders in aging
populations. World Alzheimer Report estimated that 46.8
million people worldwide live with dementia and over 9.9
million new cases are detected each year. By 2050, the total
number of people with dementia will increase to 135 mil-
lion. According to available statistics published by European
Parkinson’s Disease Association, around 6.3 million people
are affected with Parkinson’s disease worldwide. Generation
of defined neural subtypes from hiPSCs to replace affected
neurons in the brain may be an effective method in cen-
tral nervous system (CNS) disease treatment. Furthermore,
proper in vitro human cellular pathomechanisms model
would be relevant. So far many different protocols were used
for hiPSCs differentiation that consequently led to genera-
tion of broad numbers of neuronal subtypes: dopaminer-
gic, cholinergic, glutamatergic, GABAergic, motor neurons,
peripheral sensory neurons, and medium spiny neurons of
the striatum [5]. Importantly, in Alzheimer’s and Parkinson’s
diseases, dopaminergic and cholinergic neurons are the most
frequently affected groups of neurons.
Generation of functional dopaminergic neurons from
hiPSCs described in various protocols is relatively robust
and reproducible, while cholinergic neurons production still
requires optimization and increase efficiency. Herein, we will
focus on recent accomplishments in generation of dopamin-
ergic and cholinergic neurons and their potential use in the
development of novel therapies.
2. Generation of Specific Neural
Subtypes through Pluripotent Stem
Cells Differentiation
Neuronal formation and patterning are critical for the
proper wiring of the brain and they occur mostly during
embryonic neurogenesis. Neuronal progenitor cells located
in the neuroectodermal layer of the embryo are induced by
various signaling factors to differentiate into neurons and
glia. Based on the progenitor location in the developing brain,
different neuronal and glia cells are produced. For instance,
progenitor cells located in the ventral neural tube generate
motor neurons and oligodendrocytes, while interneurons
and astrocytes are produced from dorsal progenitor cells [6].
In addition to the position along the neuraxis, the fate of
single neurons depends onmany factors including epigenetic
profile and patterning factors. Unspecified progenitor cells
within the neuroectoderm can differentiate into various neu-
ral subtypes by modulating signaling pathways in which are
involved bone morphogenic protein (BMP), Wingless-Type
MMTV Integration Site Family (WNT) proteins, fibroblast
growth factor (FGF), retinoic acid (RA), and other signaling
molecules.
Numerous laboratories have established in vitro differen-
tiation protocols to generate neurons. Initially, the methods
were based on hESCs, although their use has been a source
of ethical, legal, and social controversy, because of their
derivation from early embryos. In 2007, Yamanaka’s group
has generated human iPSCs via genetic reprogramming of
somatic fibroblast cells through retroviral transduction of
four human transcription factors: POU domain, class 5,
transcription factor 1 (POU5F1), better known from its former
name octamer-binding transcription factor 4, and therefore
often abbreviated as OCT4, sex determining region Y-box 2
(SOX2), Kruppel-like factor 4 (KLF4), and c-MYC [3]. Since
this discovery, hiPSCs have been considered an important
source for the generation of neurons and many other types
of cells. iPSCs are similar to ESCs in many aspects such as the
expression of pluripotency-related genes/proteins, embryoid
body formation, teratoma formation, and capability of differ-
entiating into all three germ layers. However, the full extent
of iPSCs relation to ESCs is still being assessed.
Theoretically, iPSCs and ESCs both share the property
of pluripotency that can be equally used in human dis-
orders modeling. Despite many similarities between iPSCs
and ESCs, there are several differences that have significant
influence on new cell generation. For instance, the analysis
of gene expression profiles revealed changes between cell
lines based on their origin. The “epigenetic memory” of the
original somatic cells may cause some specific aberrations
which impede iPSC differentiation potential [7]. As a result
of prolonged in vitro propagation and the environmental
culture conditions, the genome integrity of iPSCs can be
impaired. Consequently, genetic aberrations may decrease
the reprogramming efficiency.
Despite these not fully examined issues, several alterna-
tive differentiation protocols to obtain dopaminergic (Fig-
ure 1) and cholinergic neurons from hPSCs (Figure 2) have
been developed. Human PSCs have potential to differentiate
into functionally specialized cell types through the mecha-
nism mimicking the in vivo development. Many factors such
as media composition, concentration of signaling factors,
plating cell density, and timing of differentiation andmatura-
tion process and physical parameters of culture system have
significant influence on the type and efficiency of generated
cells, such as neurons. In the next sections, we compare
the different techniques generating midbrain dopaminergic
neurons and basal forebrain cholinergic neurons fromhPSCs.
Figures 1 and 2 provide a comprehensive picture about the
used methods, chemical compounds, and laboratories which
published themethods.We also detailed whether themethod
was tested with different PSC cell sources (hESC or hiPSC).
2.1. Generation of Dopaminergic Neurons. Successful conver-
sion of PSCs to dopaminergic (DA) neurons depends on the
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Figure 1: Comparison of different protocols for deriving of midbrain dopaminergic neurons from hESCs and hiPSCs. (a) Methods based
on mechanical neural rosettes selection. Neural differentiation was induced by coculture of hPSCs on stromal cells MS5 or S2 [8] and dual
inhibition of SMADsignaling pathway (NOGGIN+TGFB inhibitor: SB431542) in the presence of knockout serum replacement (KSR) andN2
medium [9]. Rosettes structures were harvested mechanically and gently replated in the presence of growth factors. In the final step, newly
generated neural progenitor cells were differentiated into DA neurons in the absence of SHH and FGF8. (b) Methods based on the floor
plate (FP) induction. Dual SMAD inhibition (BMP inhibitor: LDN193189 + TGFB inhibitor: SB431542) and activation of WNT signaling by
SHH and GSK3B inhibitor (GSK3Bi), CHIR99021, were used for midbrain FP cell generation from hPSCs [10]. Purmorphamine treatment
was applied for FP cell patterning. hPSCs induced with LDN193189 and A83-01 (inhibitor of TGFB type I receptor ALK5) were cultured in
media supplemented with purmorphamine and FGF8 to induce floor plate cells. FP cells under stimulation with growth factors generated
DA neurons; recombinant E8 fragments of human laminin 511 (LM511-E8) supported the neural differentiation and cell survival [11]. Final
concentration of growth factors, supplements, and inhibitors may be different in the specified protocols.
patterning and signaling factors that induce gene expression
typical for endogenously developing DA neurons.
Neural stem cells (NSCs) are produced from iPSCs/ESCs
that undergo induction in coculture with stromal feeder cells
such as PA6 andMS5 [8, 16] or in feeder independent system.
Neuroepithelial structure formed by NSCs is composed of
rosettes that express neural markers like nestin (NES), paired
box 6 (PAX6), sex determining region Y-box 1 (SOX1), and
neural cell adhesion molecule (NCAM). Culture of NSCs
in chemically defined neural induction medium results in
differentiation of progenitor cells into different neuronal
subtypes.
One of the first experiments performed onNSCs revealed
that treatment of hESC-derived neural precursors with
fibroblast growth factor 8 (FGF8) and sonic hedgehog (SHH)
significantly increases the number of neurons expressing
tyrosine hydroxylase (TH) and consequently the percentage
of mature DA neurons [17]. The presence of glial cell line
derived neurotrophic factor (GDNF) in culture medium
additionally increases DA neuron differentiation [18].
Although FGF8 and SHH determine DA phenotype,
the regional identity of the DA neurons (forebrain or
midbrain phenotypes) can be specified under a chemical-
defined media composition. Recently, two groups published
protocols for generation of two different types ofDAneurons;
however, these studies used mouse ESCs (mESCs). In the
first one, progenitor cells were differentiated into midbrain
DA neurons in the presence of FGF8, SHH, and ascorbic
acid (AA) and their maturation was confirmed by dopamine
release in the medium [19]. In the second study, stromal
cells were used to induce neuronal differentiation of mESCs
in serum-free conditions without any patterning factors.
These stromal derived cells induced significant increase of
activity that is reflected in the number of TH-positive neurons
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Figure 2: Comparison of different protocols for deriving of basal forebrain cholinergic neurons from hESCs and hiPSCs. (a) Generation
of BFCNs from neurospheres through neural progenitor cell stage. Predominantly pure population of basal forebrain cholinergic neurons
(BFCNs) was derived from hPSCs by using diffusible ligands presented in the forebrain during a development [12]. Pretreatment with SHH
and FGF8 was used to differentiate hPSCs towards a forebrain progenitor fate [12]. Treatment with NGF promoted the differentiation into
functionally mature BFCNs [12, 13]. (b) Direct generation of BFCNs from cells growing in neurospheres. Neural development was induced in
neurosphere-based nonadherent differentiation in presence of mitogens and ROCK inhibitor Y27632 [14]. Neurospheres derived from hPSCs
exposed to neurotrophins, BDNF, CNTF, NT-4, and NGF, increased neuronal differentiation and cholinergic phenotype specification [15].
Composition of the basic medium can be different within the above protocols.
producing dopamine. DA neurons after transplantation into
the mouse striatum remain TH positive, thus indicating
being more forebrain-like than midbrain-like dopaminergic
neurons [20]. Additional studies showed that SOX1 positive
neuroepithelial cells derived from hESCs and being exposed
to FGF8 and SHHgenerate bipolar forebrainDAneurons that
expressed TH enzyme. Treatment of neuroepithelial cells in
precursor stage before SOX1 expression leads to formation of
midbrain DA neurons with large cell bodies and a specific
midbrain marker, engrailed 1 (EN1) [21]. In most of the
studies, the phenotype of DA neurons is confirmed by a
wide panel ofmorphological and functional characteristics as
follows: TH expression, KCl-evokedDA release, and presence
of depolarization–induced and tetrodotoxin-sensitive action
potential [8]. However, the regional identity of DA neurons
is not well examined due to the lack of reliable antibodies
(e.g., restricted detection of dopamine transporter (DAT),
maturemarker in cultured humanDA neurons) and different
time points for release of transcription factors and DA neu-
ronal marker expression. In mESCs, En1 transcription factor
expression is overlapped with TH being downregulated in
postmitotic TH neurons. Consequently, only low percentage
of TH neurons coexpressed En1 during neuronal differenti-
ation [22]. In addition, the maturation and functionality of
DA neurons are tested in 6-hydroxydopamine- (6-OHDA-)
lesioned rats. Transplantation of DA neurons derived from
hPSCs improves the behavioral deficits [11]. Analysis of grafts
suggests that the majority of DA neurons are generated from
grafted neuronal cells and some of them can be integrated
into the striatal circuitry. Dopamine release from injected
neural cells triggers functional improvements in rats [22].
Fork head box protein A2 (FOXA2) is another player
with important influence in the early development and later
maintenance of midbrain DA neurons. Midbrain dopamin-
ergic neurons with a stable phenotype defined by expression
of FOXA2, TH, and 𝛽-tubulin were generated from hESCs
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treated with low dose of retinoic acid and high activity form
of SHH. Early exposure to WNT1 and FGF8a rather than
FGF8b was required for efficient differentiation of the neural
progenitor cells from the floor plate (FP) into the midbrain
DA neurons that express FOXA2 [23].
In 2009, Chambers et al. described the rapid and efficient
conversion of hESCs and hiPSCs to neurons by the syner-
gistic action of two inhibitors of SMAD pathway, NOGGIN,
and SB431542 [9]. Single inhibition of SMAD pathway by
SB431542 is associated with a dramatic decrease in the
expression ofNANOG and increase in caudal type homeobox
2 (CDX2) that consequently result in loss of pluripotency and
differentiation through the trophoblast lineage. NOGGIN
downregulates CDX2 expression and represses BMP release
that drive trophoblast destiny. Only dual SMAD inhibition
significantly improves the neural induction of hESCs and
hiPSCs under adherent culture conditions. Exposure of cells
generated via this method to SHH at day 5 and to FGF8 at
day 9 of terminal differentiation and further culture until day
19 in medium supplemented with AA, brain derived neu-
rotrophic factor (BDNF), GDNF, transforming growth factor
beta 3 (TGFB3), and cyclic adenosine 3󸀠,5󸀠-monophosphate
(cAMP) leads to production of Tubulin, Beta 3 Class III
(TUBB3) positive neurons coexpressing TH [9].
Another method of midbrain DA neurons generation is
based on a FP strategy. FP is formed by a group of cells with
neurogenic potential located at the ventral midline of the
developing neural tube. Cells in this area secrete diffusible
molecules such as SHHandNetrin 1 (NTN1) that are involved
in neural tube patterning and guidance of extension of
commissural axons [24].The neurogenic potential of FP cells
is established by expression of transcription factors, such as
EN1, orthodenticle homeobox 2 (OTX2), FOXA2 and LIM
homeobox transcription factor 1 alpha (LMX1A), which are
involved in two regulatory feedback loops (SHH-FOXA2
and WNT1-LMX1A) [25]. Differentiation of PSCs to FP cells
and then activation of neurogenesis are an alternative way
of DA neurons generation. Human ESCs exposed to high
concentration of SHHchange themorphology and properties
towards FP cells [26]. Alternatively, SHH together withWNT
can be utilized to drive hPSCs to midbrain FP precursors.
Generated in this way, midbrain DA neurons can be main-
tained several months in vitro, and, after transplantation in
6-OHDA-lesioned mice and rats, they demonstrate complete
restoration of movement activity [10]. WNT1 expressed in
the ventral midbrain play a critical role in activating the
neurogenesis. In consequence, regulation ofWNT1 and SHH
in neural progenitor cells can lead to generation of midbrain
DA neurons via the alternative route.
2.2. Generation of Cholinergic Neurons. Basal forebrain
cholinergic neurons (BFCNs) are the major source of cortical
cholinergic input that is necessary for memory and learning.
Previous studies in animals reveal important role of BFCNs
in hippocampal neurogenesis [27] and functional synaptic
plasticity in developing cortex [28]. The largest and the
best characterized group of forebrain cholinergic neurons is
placed in the median ganglionic eminence (MGE). BFCNs
are primarily affected in Alzheimer’s disease. For this reason,
in vitro generation of cholinergic neurons from human
PSC is a crucial step for disease modeling and novel cell
replacement therapy for Alzheimer’s patients. However, the
number of BFCNs differentiated from hPSCs is still very
limited and the regional identity of generated neurons is not
well characterized.
One of the first methods for the derivation of BFCNs
from hESCs was based on the stimulation using diffusible
ligands present in the MGE at developmentally relevant
time periods [12]. The crucial step in the above experiment
was differentiation of hESC-derived neural progenitor cells
towards a forebrain progenitor fate by pretreatment with
SHH and FGF8. Neural progenitors that are generated in this
way and treated transiently with bone morphogenic protein
9 (BMP9) showed a significant increase in the expression
of BFCN markers such as choline acetyltransferase (ChAT),
acetylcholinesterase (AChE), and nerve growth factor recep-
tors (NGFR): TrkA and neurotrophin p75. Markers for other
populations of cholinergic neurons were not detected. Direct
treatment of hESCs with BMP9 without SHH/FGF8 pretreat-
ment resulted in the absence of cholinergic neurons. MGE
during development expresses some transcription factors
including LIM homeobox 8 (LHX8) transcription factor
[29] and gastrulation brain homeobox 1 transcription factor
(GBX1) that promote BFCN differentiation [30] and are
upregulated by BMP9. Transiently overexpression of LHX8
and GBX1 in SHH/FGF8 pretreated neural progenitors leads
to appearance of a highly purified population of BFCNs
with long projecting axons and coexpression of ChAT and
p75 [12]. These neurons produce acetylcholine in vitro and
form cholinergic synapses which were electrophysiologically
functional after engraftment into murine hippocampal slice
cultures.
Another method of active ChAT-positive cholinergic
neurons generation focused on neurotrophic factors. The
neurotrophins are growth factors that act by stimulating
Trk and p75 receptors, which in turn are responsible for
axonal and dendritic growth, neurotransmitter regulation,
and synaptic plasticity [31]. hESCs-derived neuronal cells
after stimulation with neurotrophins, BDNF, neurotrophin
3 (NTF3), ciliary neurotrophic factor (CNTF), and nerve
growth factor (NGF), significantly increase the proportion
of ChAT-positive neurons [15]. However, stimulation of
neural progenitors with BDNF and NGF upregulates LHX8
expression inMGE areas of the embryonic forebrain, whereas
CNTF induce LIM homeobox 6 transcription factor (LHX6)
expression in other subdomains of the MGE. Additional
expression of NK2 homeobox 1 (NKX2-1) and ISL LIM
homeobox 1 (ISL1) is associated with the development
of forebrain cholinergic neurons and coexpression of p75
receptor demonstrated the presence of BFCNs. Furthermore,
these differentiated neuronal cells produce 𝛼3, 𝛼4, and 𝛼7
subunits of nicotinic acetylcholine receptor and muscarinic
acetylcholine receptor subtypes, M1, M2, and M3, that are
displaying an important role in hESCs-derived cholinergic
neurons [15]. All the above-mentionedmethods used specific
extrinsic factors to produce cholinergic neurons in two-
dimensional cultures. However, the latest study has reported
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a novel embryoid body based differentiation system for effi-
cient induction of BFCNs [14]. Cultures of embryoid bodies
in 3-dimensional systems without any additional factors
stimulate intrinsic SHH signaling which results in expression
of NKX2-1 and LHX8 [32]. Upon terminal differentiation,
the basal forebrain specific NSCs generate electrically active
cholinergic neurons that express TUBB3, ChAT, ISL1, and
p75 and after transplantation are able to integrate into the
adult rat brain [14]. In the newest study published by Hu
et al., hPSCs were converted to NKX2-1 positive MGE cells
by using high concentration of SHH or combination of
SHH and purmorphamine. To increase the efficiency of
BFCNs generation, MGE progenitor cells were cocultured
with hPSC-derived astrocytes in the presence of NGF [33].
In the above method, around 40% of total cell population has
expressed cholinergic markers that offers a potent approach
to produce BFCNs from pluripotent cells.
3. iPSCs Providing New Tools for Developing
Treatments for Cholinergic and
Dopaminergic System Dysfunctions
Current understanding of the etiology of neurological disor-
ders is greatly expanded.However, themechanisms ofmost of
these diseases remain still unclear. Furthermore, no effective
treatments or disease-modifying therapy are available. Thus,
patient-derived human iPSCs are a good tool for generating
physiologically relevant in vitro human disease models. Stem
cells technology can be applied in disease pathomechanism
investigations, identification of potential drug targets, drug
screening platforms, and cell transplantation.
Newly generated iPSCs from patient-derived tissues are
successfully applied in modeling of human neurodegenera-
tive diseases (e.g., Alzheimer’s disease, Parkinson’s disease,
spinal muscular atrophy (SMA), amyotrophic lateral sclerosis
(ALS), and Huntington’s disease) and neurodevelopmental
disorders (e.g., familial dysautonomia, Rett syndrome, autism
spectrum disorder (ASD), and Down syndrome) (Table 1). In
recent years, the dopaminergic and cholinergic systems have
been a main focus of research in neurological pathogenesis.
Efficient generation of functional dopaminergic and cholin-
ergic neurons affected mostly in Parkinson’s disease and
Alzheimer’s/Huntington’s disease patients, respectively, can
provide a crucial tool for effective treatment of the indicated
dysfunctions.
3.1. Alzheimer’s Disease and iPSCs. Alzheimer’s disease (AD)
is an age-related neurodegenerative disorder and the most
common type of dementia in humans, affecting one in eight
adults over 65 [34]. Two main pathological hallmarks of
AD are extracellular plaques of aggregated amyloid beta
(A𝛽) protein and intracellular neurofibrillary tangles (NFTs)
composed of aggregated tau, a microtubule binding protein.
These AD features have different deleterious effect on neu-
rons. A𝛽 can disrupt synaptic plasticity including long-term
potentiation (LTP), while NFTs may compromise intracel-
lular transport and, together with A𝛽, induce mechanisms
responsible for synaptic loss and neuronal death.
Neurodegeneration in AD evolves sequentially through
certain brain regions and selected subpopulations of vul-
nerable neurons. Among the general cortical impairment,
BFCNs are one most affected cell type in AD. Decreased
level of acetylcholine (ACh) released by cholinergic nerve
terminals is associated with loss of cholinergic neurotrans-
mission and significant deterioration of cognitive functions
in AD patients. Reduced choline uptake, ACh release, and
presynaptic cholinergic deficiency correlate with accumu-
lation of A𝛽 protein and intracellular NFTs. Furthermore,
analysis of AD brain revealed reduced number of nicotinic
andmuscarinicM2ACh receptors on presynaptic cholinergic
neurons, whereas the number of M1 andM3 receptors on the
postsynaptic terminals has remained unaffected. Some stud-
ies have shown that reduced cholinergic activity may stim-
ulate higher tau hyperphosphorylation through increased
activity of protein kinase C (PKC) [35]. As a consequence
of disturbed neurotransmission balance, tau phosphoryla-
tion and A𝛽 protein accumulation are increased, and these
lead to enhanced neurodegeneration. BFCNs degeneration
contributes to attention deficits, increased spatial memory
decline, and further impairment in the coding of new
episodic memories [36].
Centrally acting drugs that inhibit cholinesterase such as
tacrine, donepezil, rivastigmine, and galantamine have been
shown to provide modest symptomatic benefit in individuals
with AD [37]. AChE inhibitors together with muscarinic
receptor agonists are able to restore cholinergic balance and
decrease A𝛽 deposition [38].
Recently, some groups have developed an AD disease
model using iPSCs. Neurons derived from iPSCs generated
from familial AD (fAD) patients carrying mutations in genes
encoding amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2) provide an innovative tool
to elucidate AD etiology and develop efficient therapeutics.
The sequential proteolytic cleavages of APP by 𝛽-
secretases and 𝛾-secretases result in the generation of A𝛽.
While 𝛾-secretases cleave C-terminal fragments of APP
(APP-CTF) which leads to production of multiple length
variants of A𝛽, longer variants of A𝛽 (A𝛽42, A𝛽43) are more
prone to aggregation than shorter ones (A𝛽38, A𝛽40) and
they are considered more pathogenic [39].
Kondo et al. generated an AD iPSCs model from patients
with E693 deletion in APP gene. Neurons with this mutation
accumulated intracellular A𝛽 oligomers that led to endoplas-
mic reticulum (ER) and oxidative stress. Furthermore, the
accumulated A𝛽 oligomers were not proteolytically resistant,
and the treatment of AD neural cells with docosahexaenoic
acid (DHA) alleviated the stress responses [40]. These results
suggest that DHA may be an effective drug for a sub-
set of patients, making iPSC technology a useful tool for
validation and identification of potential drugs. Muratore
et al. described iPSCs from fAD with mutation in APP
(V717I). This mutation results in higher APP expression,
elevated A𝛽42, A𝛽38 production, and increase in levels of
total and phosphorylated Tau in neurons [41]. In another
study, iPSCs derived neurons from fAD patients with a
duplicated APP gene showed increase of secreted A𝛽1–40,
relative level of phospho-Tau, and active glycogen synthase
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Table 1: Neurological disorders modeled with patient-specific human induced pluripotent stem cells.
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in PINK1
[53, 54, 57, 63]
SMA SMN1, SMN2




(iii) increased level of caspase
3, caspase 8, and
membrane-bound Fas ligand;




Motor neurons (i) iPSCs with SMN1 mutationfrom SMA type I patients [64, 65]









(i) ALS iPSCs with A4V SOD1
mutation;
(ii) ALS iPSCs with D90A
SOD1 mutation;
(iii) ALS iPSCs with mutation
invTDP-43 gene;







(i) Increased vulnerability to














(i) iPSCs with HTT mutation
from homozygous and
heterozygous HD patients






(i) Reduced IKAP protein
level;
(ii) cell migration deficiency;
(iii) defects in neurogenic
differentiation;
(iv) decreased in number of
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Table 1: Continued.
Disease Geneticbackground Disease related phenotype Affected neurons iPSCs model References
Rett syndrome MECP2e1,MECP2e2
(i) Reduced soma size;
(ii) altered dendritic spine
density;
(iii) dysfunction in action
potential;
(iv) alterations in synaptic
function;













(ii) altered gene expression
related to cell adhesion and
neuron differentiation;





(i) ASD iPSCs with functional
knockdown of NRXN1 gene;







(i) Alterations in neurogenesis
and synaptogenesis;




(iv) poorly developed neural
network;
(v) overproduction of reactive
oxygen species
Neurons in the brain
(i) DS iPSCs with three pairs
of chromosomes 21
(T21-iPSCs);
(ii) isogenic iPSCs from DS
individuals;
(iii) DS iPSCs with trisomy 21
deletion through TKNEO;










(i) iPSCs from schizophrenia
patients;
(ii) SZ iPSCs with a mutation
in DISC1 gene
[81, 82]
kinase 3 beta (GSK3B). Treatment of the neurons with 𝛽-
secretase inhibitors significantly reduced the relative level
of phospho-Tau and active GSK3B [42]. fAD-derived iPSCs
with PSEN1 (A246E) and PSEN2 (N141I) mutations were
also established. In both cases, neuronal cells had increased
A𝛽42 secretion and A𝛽42/40 ratio [43]. The treatment with
𝛾-secretase inhibitors reduced A𝛽40 and A𝛽42 production
in mutant neurons. The above-presented findings on iPSCs
derived from patients are a good method of recapitulation of
AD phenotype in vitro and can be used for drug discovery
and improve disease modeling.
In recent time, few groups successfully generated iPSCs
from sporadic AD (sAD) patients that represent more than
95% of all AD cases. sAD iPSCs showed similar phenotype
to fAD iPSCs including increase of secreted A𝛽, high level of
ER and oxidative stress, and accumulation of enlarged RAB5-
positive early endosomes [42]. However, there is still limited
information about the clinical onset and course of sAD.
Newly developed models, mostly based on 2-dimensional
(2D) culture system, may not reflect affected neurons in the
brain. Due to the limited studies, it is difficult to predict
whether neurons derived from sAD iPSCs show pathological
phenotype and are able to reveal molecular basis of disease
development. To evaluate a real value of sAD derived iPSCs,
a long-term culture in 3-dimensional (3D) system may be
required. Furthermore, integration of microglia in neuronal
culture together with environmental cues mimicking sAD
risk factors might significantly improve in vitro-based exper-
imental sAD models.
According to the recent data, animal and nonneuronal
cellularmodels used in pharmaceutical compound validation
cannot sufficiently model the drug responses of human neu-
rons. Therefore, there is an increasing trend to test potential
drugs for the treatment of Alzheimer’s disease using patient-
derived iPSC based systems.
Based on the fact that mutation in APP or in the 𝛾-
secretases components, PSEN1 and PSEN2, lead to increased
A𝛽42/A𝛽40 ratio and total A𝛽 level, several drugs such as
𝛽-secretase and 𝛾-secretase inhibitors have been developed
[44, 45]. Nonsteroidal anti-inflammatory drugs (NSAIDs)
were identified as 𝛾-secretase modulators (GSMs) that lower
A𝛽42 production by targeting 𝛾-secretase or APP [46].
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The studies performed on iPSC-derived neurons from AD
patients have shown that indometacin, ibuprofen, diclofenac,
and flurbiprofen significantly reduced the A𝛽42/A𝛽40
ratio [46]. Treatment with 𝛾-secretase inhibitor, N-[N-(3,5-
difluorophenacetyl)-1-alanyl]-S-phenylglycine t-butyl ester
(DAPT), or 𝛾-secretase activating protein (GSAP) inhibitor,
imatinib, resulted in strong decrease of A𝛽40 and A𝛽42 level.
Inhibition of A𝛽40 secretion by SC-560 led to increased
A𝛽42/A𝛽40 ratio. Other tested molecules including aspirin,
naproxen, and Rho-associated coiled-coil forming protein
serine/threonine kinase (ROCK) inhibitor Y-27632 had no
significant effect on the neurons [46].
3.2. Parkinson’s Disease and iPSCs. Parkinson’s disease (PD)
is the second most common progressive neurodegenerative
disorder. Patients with PD manifest a wide range of symp-
toms, encompassing slowness of movement, rigidity, a low-
frequency rest tremor, and difficulty with balance. These
crucial motor impairments of PD are due to the degeneration
of dopamine containing neurons in the substantia nigra pars
compacta (SNC)with an accompanying loss of dopamine and
its metabolites in the striatum [47].
The majority of PD cases are sporadic; only 10–20%
patients present familial monogenic form of disease. Muta-
tions in genes, synuclein alpha (SNCA), leucine-rich repeat
kinase 2 (LRRK2), Parkin RBR E3 Ubiquitin Protein Lig-
ase (PARK2), PTEN-induced putative kinase 1 (PINK1),
ubiquitin carboxyl-terminal esterase L1 (UCHL1), and beta-
glucocerebrosidase (GBA), lead to pathogenic changes in the
brain [48].
At the pathological level, PD is characterized by the
cytoplasmic accumulation of aggregated proteins with a
halo of radiating fibrils and a less defined core known as
Lewy body. Another PD-specific feature is the increase of
oxidative stress, which is caused by glutathione depletion,
iron deposition, increased markers of lipid peroxidation,
oxidative DNA damage and protein oxidation, and decreased
expression and activity of mitochondrial complex 1 in the
SNC [49].
Several groups revealed dysfunction of basal forebrain
cholinergic system in PD patients that was confirmed by the
presence of Lewy body in neurons of the nucleus basalis of
Meynert, the main source of cholinergic neurons in the brain
[50]. Additional study has indicated a loss of presynaptic
cholinergic markers in cortex, decrease of muscarinic and
nicotinic receptor binding sites, and reducedChAT activity in
the neocortex, hippocampus, and substantia nigra. Impaired
distribution of pre- and postsynaptic cholinergic receptors
can correlate with PD attenuation.
Recent data have shown that the loss of DAneurons in PD
corresponds with alterations of M4 receptor in cholinergic
neurons. In consequence, ACh level in the striatum is
increased and that contributes to the development of the
motor signs like tremors and dyskinesia in PD patients [35].
Unlike most other neurodegenerative disorders, there is
an effective temporary symptomatic treatment for PD con-
sisting of dopamine replacement with levodopa or dopamine
agonists [51]. On the other hand, since the neurodegeneration
in PD is progressive and there is no efficient regenerative
therapy, patients eventually become quite disabled.Therefore,
the inhibition of postsynaptic muscarinic receptor resulting
in ACh secretion decrease and upregulation of presynaptic
nicotinic receptors secreting dopamine can provide a new
therapeutic strategy in PD treatment.
The iPSC technologies provide an opportunity to study
PD phenotypes and mechanisms in familial and sporadic
cases and to identify potential drugs.
One of the first models of familial PD was iPSCs
generated from a patient with triplication of the SNCA
gene, which encoded a synaptic vesicle-associated protein in
Lewy bodies. DA neurons derived from this patient exhibit
increased SNCA expression and susceptibility to oxidative
stress [52]. Other researchers generated iPSCs from patients
with the most common SNCA mutation, A53T. Compared
with controls, these cells produced more nitric oxide and
3-nitrotyrosine (3-NT) and showed accumulation of ER-
associated degradation substrates [53]. DA neurons differen-
tiated from iPSCs derived from patients with G2019S muta-
tion inLRRK2 gene demonstrated increased expression of key
oxidative stress response genes: HSPB1, NOX1, MAOB, and
upregulation of SNCA. The mutant neurons were also more
sensitive to stress agents: hydrogen peroxide, the proteasome
inhibitor MG132, and 6-OHDA [54]. Another study showed
that DA neurons developed from iPSCs of either sporadic PD
or LRRK2 PD showed similar phenotypes including higher
level of SNCA, the accumulation of SNCA, and reduced
numbers of neurites [55]. If these results will be reproducible,
they may give us a possibility to model also idiopathic PD
cases in the future. Despite the unknown causes of this
disorder, a small proportion of idiopathic PD cases can be
attributed to known genetic factors. Although generation
of iPSCs from idiopathic PD patients was established, it
is still not confirmed whether PSC-derived DA neurons
demonstrate phenotypes that are evidently detectable and
related to PD in vitro [56]. Due to the unknownmechanisms
leading to sporadic PD, thatmay result from a combination of
genetic and environmental factors, the use of isogenic control
for comparative studies is not possible. However, an increased
number of cell lines generated frompatients couldmake iPSC
models more reliable in the context of complex diseases such
as sporadic PD.
The main DA neurons were also generated from iPSCs
carrying mutation in PINK1. This gene encodes a mitochon-
drial kinase which protects cells against mitochondrial stress
and control degradation of mitochondria. DA neurons with
this defect upon treatment with the mitochondrial stress
inducer increase level of peroxisome proliferator-activated
receptor gamma, coactivator 1 alpha (PPARGC1A) regulator
of mitochondrial biogenesis, and the number of mitochon-
dria [57]. The above results show that not only genetic
background of neurons but also their exposure to the relevant
stressors may be necessary for proper modeling of disease
phenotype using iPSCs. DA neurons carrying the mutation
in PARK2 gene increase the transcription of monoamine
oxidases and significantly block DA uptake that leads to
higherDA release. Insertion of the correct form of themutant
gene rescues the phenotype. It suggests that PARK2 con-
trols dopamine neurotransmission and suppresses dopamine
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oxidation [58]. These results provide a physiologically rele-
vant platform to screen the novel targets of disease-modifying
therapies in PD.
Recently, it was shown that iPSCs can be successfully
transplanted into PD animal models. iPSCs efficiently stim-
ulated into NPCs and injected into the brain give rise
to neuronal and glia cells that are functionally integrated
with the neural tissues and have mature neuronal activity.
Midbrain DA neurons differentiated from hiPSCs upon
transplantation into the adult brain were able to improve the
behavioral phenotype of rats affected by PD [59]. Another
study showed that DA neurons generated from PD iPSCs
and transplanted into the striatum of 6-OHDA-lesioned rats
developed axons projections [60]. Rhee et al. demonstrated
that transplantation of DA neurons derived from protein-
based hiPSCs into rats with striatal lesions can rescue motor
deficits [61]. In 2005, Kishi et al. have demonstrated a possible
role of estrogen in the transplantation ofNSCs for Parkinson’s
disease. 17𝛽-estradiol, estrogen hormone, increased the num-
ber of TH-positive DA neurons in vitro. The above effect was
abrogated by an estrogen receptor antagonist, ICI182780, that
confirmed a role of ERs in differentiation of DA neurons [62].
Due to the presence of ERs inNSCs andDAneurons, increase
in TH-positive neurons was associated with the supporting
effect of estrogen on neural differentiation of iPSCs and DA
neuron maturation [62].
3.3. Huntington’s Disease and iPSCs. Huntington’s disease
(HD) is an inherited progressive disorder that affects around
1 in 10,000 people. The specific features of HD comprise
dystonia, motor incoordination, and cognitive and emotional
impairments [83]. Cause of the disorder is an expanded CAG
triplet coding for polyglutamine in the HD gene product,
called the huntingtin (HTT) protein. The normal function of
this protein is poorly understood with some evidences of an
involvement with cytoskeletal function.
At the pathological level, HD is characterized by selective
neuronal vulnerability. The first area affected by HD is the
caudate-putamen that is part of the corpus striatum region.
Within this brain region, medium spiny GABA neurons are
severely impaired,with up to 95% loss in later stages of disease
(reviewed in [84]).Moreover, there are intranuclear inclusion
bodies and perinuclear and neuritic aggregates ofHTT inHD
neurons. Early genetic studies onHD revealed that the length
of the triplet repeat expansion of CAG is positively correlated
with the severity of the disease. Glutamate toxicity, oxidative
stress, and autophagy inhibition are stressors that stimulate
CAG expansion and result in higher cell toxicity [5].
Some studies in human and mouse models indicated
that also cholinergic system is affected in HD patients. The
cholinergic neuron abnormalities were demonstrated by the
observations that ChAT activity is reduced in the striatal
tissue of the brain and ACh release is significantly decreased
[85]. It was confirmed that vesicular acetylcholine transporter
(VAChT) and ChAT genes are regulated by the repressor
element-1 silencing transcription factor/neuron restrictive
silencer factor (REST/NRSF) [86]. Interaction of REST/NRSF
with mutant HTT protein leads to repression of few neuronal
specific genes such as BDNF and can cause a decrease of
cholinergicmarker expression. During the studies performed
by Smith et al., decreased level of ChAT in striatum of
HD mice correlated with the amount of HTT aggregates
in cholinergic neurons. These results suggest that the defect
observed in cholinergic neurons depends on the mechanism
controlled by mutated HTT [85].
Recently, AChE inhibitors such as tacrine were proposed
to be potential drugs for HD treatments due to their ability
to restore the cholinergic system. Choline, physostigmine,
donepezil, and other potential drugs in HD treatment are
being tested now; however, their ability to restore a memory
and reduce the hyperkinesia seems to be very limited [35].
HD neural cells derived from iPSCs displayed disease
associated phenotype including changes in metabolism, elec-
trophysiology cells adhesion, and cell toxicity. Differentiated
HDcells with expandedCAG repeats showed changes in gene
expression, including cadherin family and TGFB pathways.
Additionally, cells had abnormalities in oxygen consumption
and were more vulnerable to cell stressors and BDNF with-
drawal [69]. In other studies, HD-generated iPSCs presented
impaired lysosomal activity, mitochondrial fragmentation,
and alterations in transcription repressor activity [5]. Park et
al. differentiated HD specific neural stem cells derived from
patient iPSC into striatal neurons. In these neuronal cells, an
enhanced caspase 3/7 activity was detected [70]. HD iPSCs
after treatment with inhibitor ofmitochondrial fission related
protein: dynamin 1-like (DNM1L) increased cell viability [66].
During in vivo studies performed by Jeon and coworkers,
HD-derived neuronal progenitor cells were transplanted into
HD rat with excitotoxic striatal lesions. Behavioral recovery
was observed, even though the injected cells have revealed
HD phenotype [87]. Above studies suggest that mutation
correction in iPSCs is required for effective treatment of HD.
Drug screening and test of novel therapies using HD
iPSC-derived neuronal cells include application of stressors
such as glutamate toxicity, oxidative stress, DNA damage, or
growth factor withdrawal [88] to test molecules counteract-
ing the effects. For instance, the tumor necrosis factor-alpha
(TNF𝛼) inhibitor XPro-1595 decreased cytokine induced
apoptosis in neurons derived from iPSCs with 43 CAGs
[89]. Adenosine receptor 2A agonists CGS-21680 and APEC




by decreased 𝛾-H2A Histone Family Member X (𝛾H2AX)
induction and caspase 3 cleavage [90].
Other studies have shown that G-protein coupled recep-
tor 52 (GPR52) is involved in mutant huntingtin toxi-
city. GPR52 knockdown as well as the microRNA 196a
(miR196a) reduced huntingtin aggregates in neuronal cul-
ture [91]. Additionally, GPR52 knockdown lowered caspase
3 activity in response to BDNF withdrawal. Moreover,
the number of condensed nuclei after BDNF withdrawal
was reduced by peroxisome proliferator-activated receptor
gamma (PPAR𝛿) activator (KD3010) [92]. Many research
groups have described drug effect of BDNF or FGF/LIF
withdrawal, considered as a stress factor on cell survival [88].
Inhibitor of ataxia-telangiectasia mutated (ATM) protein, a
kinase involved in the DNA damage response, apoptosis, and
cellular homeostasis, KU60019, applied on the 109 and 180
CAGmixed neuronal cell cultures has shown reduced BDNF
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withdrawal-induced increases in TUNEL-positive nuclei and
reduced caspase 3 activity [93]. In 2015, Ring at al. demon-
strated that TGF-𝛽 signaling pathway is altered in HD NSC
with 72 CAGs that leads to higher expression of TGF-𝛽.
Furthermore, TGF-𝛽1 plays neuroprotective role in the NSC
models and together with netrin-1 can reduce caspase 3/7
activity [94].
Effects of compounds on PSCs phenotypes not related
to a stressor addition have been tested by Charbord et al.
The studies were associated with increased activity of the
transcriptional repressor REST/NRSF binding to repressor
element-1 (RE1) sequences in HD. High-throughput screen-
ing of thousands of selected compounds identified two
benzoimidazole-5-carboxamide derivatives that inhibited
REST silencing in a RE1-dependent manner. Treatment of 72
CAGNSCswith X5050 inhibitor, targeted REST degradation,
increased the expressions of BDNF and other REST-regulated
genes [95]. In 2013, Guo et al. developed a selective inhibitor
(P110-TAT) of the mitochondrial fission protein dynamin-
related protein 1 (DRP1). Treatment of iPSC-derived neurons
from HD patients with P110-TAT reduced mitochondrial
fragmentation and improved mitochondrial function. Fur-
thermore, P110-TAT increased cell viability and reduced the
extent of neurite shortening in neuronal culture [96].
4. Concluding Remarks
The iPSC technology is a novel and complementary approach
to studying neurological diseases.
Generation of human iPSC-derived neuronal cells
enables the understanding of neural development and neuro-
pathological processes in a more accessible manner than
has previously been achieved. Rapid progress is being
made in improving techniques for differentiation of iPSCs
towards diverse populations of neural subtypes. Genera-
tion of hiPSC-derived cholinergic neurons will broaden
our knowledge about mechanisms of cholinergic function
during development and synaptic plasticity. The ability to
selectively control neuronal differentiation of PSCs into func-
tional neurons expressing cholinergic neurotransmitters and
receptors is a significant step in understanding neurodegen-
erative diseases. Furthermore, it can be used for the develop-
ment of cell replacement therapy for Alzheimer’s disease and
high-throughput screening for agents that promote BFCNs
survival. The in vitro generated biologically functional
DA neurons offer a renewable source for toxicological
and pharmaceutical drug screening. They may provide an
effective tool in the development of sustainable therapies
for disorders that affect the DA system such as Parkinson’s
disease.
Despite the above-mentioned advantages, there are still
some hurdles in expanding the use of iPSCs to study neuro-
logical diseases. First, there is lack of uniformity in culture
techniques and induction methods that make unclear how
reproducible differentiation protocols are. Methods based
on neuronal differentiation in three-dimensional systems
seem to be more efficient than adherent two-dimensional
cultures. However, it is not determined which system is
more adequate for in vivo environment. Second, a better
characterization of a given neural subtypes is needed as well
as verification whether newly generated neurons are able
to integrate into the circuitry of a host organism. Neurons
derived fromhiPSCs required fewweeks of culture to become
electrophysiologically active and fewmonths to integrate into
the host neural environment after transplantation. Thus, the
proper model system must be considered for assessing the
function of human stem cell derived neurons and evaluating
their safety in the long-term culture. Another difficulty is
related to a variability of the iPSCs phenotypes within the
cell lines, even if they are derived from the same patient.
The iPSC variations can originate from different sources
during iPSC generation and maintenance. Therefore, strong
emphasis should be placed on demonstrating that phenotype
of iPSC-derived neurons is associated with specific genetic
background and not with this variability.The potential source
of the line-to-line variation is the reprogramming process
that may disturb the genomic and epigenetic stability and
potentially introduces de novo epigenetic variations. Fur-
thermore, during a clonal selection process, clones carrying
genetic defects can be selected, while the increasing passage
numbermight introduce genetic alterations that facilitate cell
propagation. Such genetic and epigenetic variations between
different iPSCs lines may affect the differentiation potential
and undermine the iPSCs accountability in downstream
applications. Thus, several iPSC lines from the same indi-
vidual are necessary to monitor the phenotypic variability
between these lines.
Despite the above limitations, patient-specific iPSC-
derived neurons provide an opportunity to model disease
process in vitro. iPSCs carrying the genetic background and
epigenetic pattern of the host individual can be a good tool to
study themultifactorial diseases. One of themost challenging
issues in disease modeling is the identification of the disease
phenotype of neurons from patients. The difficulties are
particularly visible in studying neurodegenerative disorders
which evolve over several decades in vivo.Therefore, a recon-
struction of cellular environment and interactions between
the cells under the disease conditions can facilitate a proper
phenotype development.
In conclusion, recent studies confirmed that iPSCs can
accelerate drug discovery and might be applied for cell
transplantation. In particular, ESC/iPSC-derived cholinergic
and dopaminergic interneurons resulted in improved neu-
rodegenerative diseases models, thus complementing animal
models and accelerating the translation towards patient
subgroup stratified clinical trials. We predict that iPSCs
derived neural cells will be suitable to be used in various
applications of in vitro diseasemodeling, high-throughput or
high-content drug, and toxicology screening and potentially,












ALS: Amyotrophic lateral sclerosis
APP: Amyloid precursor protein
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ATM: Ataxia-telangiectasia mutated
BDNF: Brain derived neurotrophic factor
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DRP1: Dynamin-related protein 1
EGF: Epidermal growth factor
EN1: Engrailed 1
ER: Endoplasmic reticulum
fAD: Familial Alzheimer’s disease
FGF: Fibroblast growth factor
FGF8: Fibroblast growth factor 8
FOXA2: Fork head box protein A2
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GBA: Beta-glucocerebrosidase
GBX1: Gastrulation brain homeobox 1
GDNF: Glial cell line derived neurotrophic factor
GPR52: G-protein coupled receptor 52
GSK3B: Glycogen synthase kinase 3 beta
GSK3Bi: GSK3B inhibitor
GSMs: 𝛾-Secretase modulators
GSAP: 𝛾-Secretase activating protein
HD: Huntington’s disease
hESC: Human embryonic stem cell
hiPSC: Human induced pluripotent stem cell
hPSC: Human pluripotent stem cell
HTT: Huntingtin
ISL1: ISL LIM homeobox 1
KLF4: Kruppel-like factor 4
KSR medium: Knockout serum replacement
Lhx6: LIM homeobox 6
Lhx8: LIM homeobox 8
LM511-E8: Recombinant E8 fragments of human
laminin 511
LMX1A: LIM homeobox transcription factor 1
alpha
LRRK2: Leucine-rich repeat kinase 2
LTP: Long-term potentiation
mESC: Mouse embryonic stem cell
MGE: Median ganglionic eminence
miR196a: microRNA 196a
NCAM: Neural cell adhesion molecule
NES: Nestin
NFT: Neurofibrillary tangle
NGF: Nerve growth factor
NGFR: Nerve growth factor receptor
NKX2-1: NK2 homeobox 1
NRSF: Neuron restrictive silencer factor
NSAIDs: Nonsteroidal anti-inflammatory drugs




OCT4: Octamer-binding transcription factor 4
OTX2: Orthodenticle homeobox 2
PARK2: Parkin RBR E3 Ubiquitin Protein Ligase
PAX6: Paired box 6
PD: Parkinson’s disease
PDL: Poly-D-Lysine
PKC: Protein kinase C
PPAR𝛿: Peroxisome proliferator activated receptor
gamma
PPARGC1A: Peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha
PINK1: PTEN-induced putative kinase 1
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REST: Repressor element-1 silencing
transcription factor
ROCK: Rho-associated coiled-coil forming
protein serine/threonine kinase
sAD: Sporadic Alzheimer’s disease
SHH: Sonic hedgehog
SMA: Spinal muscular atrophy
SNC: Substantia nigra pars compacta
SNCA: Synuclein alpha
SOX1: Sex determining region Y-box 1
SOX2: Sex determining region Y-box 2
TGFB3: Transforming growth factor, beta 3
TH: Tyrosine hydroxylase
TNF𝛼: Tumor necrosis factor-alpha
TUBB3: Tubulin, Beta 3 Class III
UCHL1: Ubiquitin carboxyl-terminal esterase L1
VAChT: Vesicular acetylcholine transporter
WNT: Wingless-Type MMTV Integration Site
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